Sign up USA
Proactive Investors - Run By Investors For Investors

Q BioMed strikes development deal with Sphaera Pharma to advance toddler non-verbal disorder drug

The firm has struck a partnership with Sphaera Pharma to develop a new analog of the drug QBM-001
Q BioMed strikes development deal with Sphaera Pharma to advance toddler non-verbal disorder drug
There are around 20,000 new cases of pediatric developmental nonverbal disorder in the USA each year and a similar amount in Europe

Q BioMed Inc (OTCMKTS:QBIO) announced progress on its recently acquired candidate to prevent a non-verbal disorder related to autism in toddlers.

It has struck a partnership with Sphaera Pharma to develop a new analog of the drug QBM-001 - the license for which it acquired from the firm ASDERA in April this year.

"The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers that become non- or minimally verbal for the rest of their lives," said Denis Corin, chief executive  of Q BioMed.

There are around 20,000 new cases of pediatric developmental nonverbal disorder in the USA each year and a similar amount in Europe.

Individually, the economic costs for toddlers that become non- or minimally verbal is US$10mln on average per person over their life.

Sphaera Pharma will use its patented platform to produce a novel analog that aims to reduce or eliminate potential side effects and can reduce the amount of product a toddler needs to take daily.

Preclinical testing is already underway, highlighted Q BioMed and a final product is scheduled to be ready by the middle of October.

This will put Q BioMed on a path to file an IND (investigational new drug) towards the end of 2017 or the beginning of 2018.

"Sphaera Pharma's platform has had great success by providing improved safety and efficacy profile for drugs being developed by biopharma companies," said Dr. Sundeep Dugar, chief executive of Sphaera Pharma.

"Being able to employ our technology to ensure a safer product that could allow these toddlers to speak is inspiring to our whole team."

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
1511808112_surgeon.jpg
November 27 2017
In a letter to stakeholders, George Adams, the president and chief executive, highlighted that the device would "reduce the cost of its equipment significantly"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use